Icrucumab

Last updated
Icrucumab
Monoclonal antibody
Type Whole antibody
Source Human
Target VEGFR-1
Clinical data
Other namesIMC-18F1
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6514H10024N1756O2032S42
Molar mass 146796.63 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors. [1] [2]

Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials. [3]

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab" (PDF). American Medical Association.
  2. ↑ LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S (April 2014). "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study". Invest New Drugs. 32 (2): 303–11. doi:10.1007/s10637-013-9998-8. PMID   23903897. S2CID   34756277.
  3. ↑ Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.